We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

210 hedge funds and large institutions have $3.25B invested in Vir Biotechnology in 2021 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 77 increasing their positions, 57 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 23

35% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 57

20% more funds holding

Funds holding: 175 → 210 (+35)

17% more funds holding in top 10

Funds holding in top 10: 6 → 7 (+1)

2.65% more ownership

Funds ownership: 57.02% → 59.67% (+2.7%)

0% more capital invested

Capital invested by funds: $3.24B → $3.25B (+$10.1M)

3% less call options, than puts

Call options by funds: $37M | Put options by funds: $38.2M

Holders
210
Holders Change
+35
Holders Change %
+20%
% of All Funds
3.23%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
59
Increased
77
Reduced
57
Closed
23
Calls
$37M
Puts
$38.2M
Net Calls
-$1.19M
Net Calls Change
-$14M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$79.7M
2
Morgan Stanley
Morgan Stanley
New York
+$42.6M
3
Millennium Management
Millennium Management
New York
+$31.4M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$18.9M

Top Sellers

1
Capital International Investors
Capital International Investors
California
-$126M
2
APF
Alaska Permanent Fund
Alaska
-$49.8M
3
SIAU
SB Investment Advisers (UK)
United Kingdom
-$15.7M
4
OIM
Oracle Investment Management
Connecticut
-$12.6M
5
Bank Julius Baer & Co
Bank Julius Baer & Co
Switzerland
-$11.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
SIAU
1
SB Investment Advisers (UK)
United Kingdom
$930M -$15.7M -400,022 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$307M +$4.3M +109,814 +2%
Temasek Holdings
3
Temasek Holdings
Singapore
$232M -$8.77M -223,754 -4%
Capital International Investors
4
Capital International Investors
California
$231M -$126M -3,218,090 -37%
BlackRock
5
BlackRock
New York
$222M +$5.81M +148,420 +3%
Baillie Gifford & Co
6
Baillie Gifford & Co
United Kingdom
$164M +$619K +15,809 +0.4%
AllianceBernstein
7
AllianceBernstein
Tennessee
$110M +$18.9M +483,261 +23%
State Street
8
State Street
Massachusetts
$106M +$9.41M +240,241 +11%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$86M +$79.7M +2,033,400 +9,371%
APF
10
Alaska Permanent Fund
Alaska
$79M -$49.8M -1,272,438 -36%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$51.6M +$1.41M +36,062 +3%
Morgan Stanley
12
Morgan Stanley
New York
$51.5M +$42.6M +1,086,524 +752%
Millennium Management
13
Millennium Management
New York
$40.5M +$31.4M +802,652 +486%
OIM
14
Oracle Investment Management
Connecticut
$36M -$12.6M -320,349 -27%
Charles Schwab
15
Charles Schwab
California
$30.4M +$1.09M +27,892 +4%
APM
16
Avidity Partners Management
Texas
$29.3M +$7.25M +185,000 +36%
GF
17
Gates Foundation
Washington
$28.4M – – –
N
18
Nuveen
North Carolina
$26M +$11.2M +285,300 +85%
Northern Trust
19
Northern Trust
Illinois
$25.9M -$123K -3,142 -0.5%
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$25M +$22M +560,914 +1,536%
Citadel Advisors
21
Citadel Advisors
Florida
$24.7M +$17.7M +451,777 +325%
Goldman Sachs
22
Goldman Sachs
New York
$23.3M -$2.3M -58,713 -10%
TAMH
23
Taikang Asset Management (HK)
Hong Kong
$22.3M – – –
Norges Bank
24
Norges Bank
Norway
$20.8M +$4.06M +103,751 +26%
Voloridge Investment Management
25
Voloridge Investment Management
Florida
$14.9M +$6.02M +153,578 +76%
1
2 3 4 5

VIR Hedge Fund Activity: Q4 2021 in Review

210 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2021, worth a combined $3.25B — up 0.31% from $3.24B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new VIR positions and 23 closed out — a net gain of 36 holders — while 77 added to existing stakes and 57 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $79.7M. The largest seller was Capital International Investors, cutting an estimated $126M.

  • 210 institutional investors held Vir Biotechnology (VIR) as of Q4 2021, up from 175 in Q3 2021.
  • Funds reported $3.25B of Vir Biotechnology stock for Q4 2021, up 0.31% quarter-over-quarter.
  • 59 funds opened new Vir Biotechnology positions in Q4 2021 and 23 closed out, a net change of +36 holders.
  • The largest Vir Biotechnology buyer in Q4 2021 was Point72 Asset Management, an estimated $79.7M added.
  • The largest Vir Biotechnology seller in Q4 2021 was Capital International Investors, an estimated $126M sold.

Based on aggregated 13F filings for Q4 2021.